Celltrion

Areas of focus for research sites in 2017

Monday, January 30, 2017

The Pulse on Site Success by Christophe Berthoux

As 2016 came to a close, many of us spent time reflecting and forecasting for the next year. The clinical research industry has continued to experience significant change and 2016 was no exception. We explored many topics, most notably patient-centricity, methods aimed at streamlining processes and proactive ways to handle study startup. These themes will continue to remain industry discussion topics and new site models will set trends moving forward.

[Read More]

Why is there such inefficiency in site selection?

Thursday, December 15, 2016

This question is often asked about an industry deeply root­ed in paper-based, spreadsheet tools for clinical trial conduct. Study teams have continued to rely on these older tools and relation­ships with principal investigators that have developed over time to select sites, building an institu­tional knowledge about specific sites based on previous studies.

[Read More]

Teva, Celltrion partner on biosimilar commercialization

Thursday, October 6, 2016

Teva Pharmaceutical Industries, Celltrion and Celltrion Healthcare have entered into an exclusive partnership to commercialize two of Celltrion’s mAb biosimilar candidates in the U.S. and Canada. CT-P10 is a proposed mAb biosimilar to Rituxan (rituximab), which is used to treat patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), Wegener’s granulomatosis and microscopic polyangiitis (MPA).

[Read More]